- Home
- BCYC vs PRAX Comparison
BCYC vs PRAX Comparison
Compare BCYC & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCYC
- PRAX
- Stock Information
- Founded
- BCYC 2009
- PRAX 2015
- Country
- BCYC United Kingdom
- PRAX United States
- Employees
- BCYC N/A
- PRAX N/A
- Industry
- BCYC Biotechnology: Pharmaceutical Preparations
- PRAX Biotechnology: Pharmaceutical Preparations
- Sector
- BCYC Health Care
- PRAX Health Care
- Exchange
- BCYC Nasdaq
- PRAX Nasdaq
- Market Cap
- BCYC 566.5M
- PRAX 599.7M
- IPO Year
- BCYC 2019
- PRAX 2020
- Fundamental
- Price
- BCYC $8.22
- PRAX $38.55
- Analyst Decision
- BCYC Buy
- PRAX Strong Buy
- Analyst Count
- BCYC 10
- PRAX 10
- Target Price
- BCYC $25.00
- PRAX $116.50
- AVG Volume (30 Days)
- BCYC 333.0K
- PRAX 320.6K
- Earning Date
- BCYC 05-01-2025
- PRAX 05-02-2025
- Dividend Yield
- BCYC N/A
- PRAX N/A
- EPS Growth
- BCYC N/A
- PRAX N/A
- EPS
- BCYC N/A
- PRAX N/A
- Revenue
- BCYC $25,722,000.00
- PRAX $8,122,000.00
- Revenue This Year
- BCYC N/A
- PRAX N/A
- Revenue Next Year
- BCYC $1.83
- PRAX N/A
- P/E Ratio
- BCYC N/A
- PRAX N/A
- Revenue Growth
- BCYC N/A
- PRAX 270.02
- 52 Week Low
- BCYC $6.10
- PRAX $26.70
- 52 Week High
- BCYC $28.67
- PRAX $91.83
- Technical
- Relative Strength Index (RSI)
- BCYC 49.16
- PRAX 53.72
- Support Level
- BCYC $8.00
- PRAX $35.21
- Resistance Level
- BCYC $8.73
- PRAX $38.90
- Average True Range (ATR)
- BCYC 0.48
- PRAX 2.09
- MACD
- BCYC 0.02
- PRAX 0.07
- Stochastic Oscillator
- BCYC 33.33
- PRAX 69.58
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.
About PRAX Praxis Precision Medicines Inc.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB.